Articles

This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer.

Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer.

Liquid biopsies may offer the opportunity to obtain information regarding specific genetic mutations in intrahepatic cholangiocarcinoma.

On May 19, 2020, the FDA approved a new indication for olaparib (Lynparza; AstraZeneca), a PARP inhibitor, for the treatment of men with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic HRR mutation, as determined by an FDA-approved test, whose disease progressed after enzalutamide (Xtandi) or abiraterone acetate (Zytiga) therapy. Olaparib is the first FDA-approved PARP inhibitor for prostate cancer.

On May 18, 2020, the FDA approved a new indication for atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) whose tumor has high PD-L1 expression (PD-L1 stained ≥50% of tumor cells or PD-L1 stained tumor-infiltrating immune cells covering ≥10% of the tumor area), and no EGFR or ALK genomic aberrations, as determined by an FDA-approved test.

The federal government is an active participant in shaping and delivering healthcare policy. The panelists in this session addressed the government’s response to COVID-19 and weighed in on some of the issues that their agencies frequently encountered as medical practices grapple with the new normal.

Nurses are on the front lines like no other healthcare personnel. In this panel, distinguished nursing professionals discussed topics and issues that have arisen during the pandemic. Led by healthcare educator Lillie D. Shockney, the comprehensive panel covered some of the myriad issues nurse navigators confront now, including rising cancer rates in an aging population, and a decline in numbers of oncology nurses and oncologists.